8-K: Travere Therapeutics Reports Strong 2025 Sales, Eyes FSGS Approval

Travere Therapeutics announced preliminary Q4 and full-year 2025 financial results, highlighted by record FILSPARI sales and progress towards FSGS approval and a pivotal HCU study restart.

Summary

• Total U.S. net product sales for the fourth quarter of 2025 are expected to be approximately $127 million.
• Total U.S. net product sales for the fiscal year 2025 are expected to be approximately $410 million.
• The company ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities.
• FILSPARI (IgAN) reached an all-time high of 908 new patient start forms (PSFs) during Q4 2025.
• Preliminary U.S. net product sales of FILSPARI totaled approximately $103 million in Q4 2025, representing 108% growth year-over-year, and approximately $322 million for the full year 2025.
• In October 2025, the company received a $40 million milestone payment from its collaborator CSL Vifor.
• The PDUFA target action date for FILSPARI in FSGS is January 13, 2026, with responses to recent FDA information requests currently under review.
• The pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU is on track to restart in the first quarter of 2026 following manufacturing optimization.
• The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and expects to announce complete full year 2025 financial results in February.

Sentiment

Score: 8

Explanation: The company reported strong preliminary financial results for FILSPARI, including significant year-over-year growth and record patient starts. Progress towards FSGS approval and the restart of a pivotal Phase 3 study for HCU are positive pipeline developments. The cash position is healthy. The only minor concern is the FDA's additional information request for FSGS, which has been addressed, but introduces a slight uncertainty.

Positives

• Strong preliminary total U.S. net product sales for 4Q 2025 of approximately $127 million and FY 2025 of approximately $410 million.
• FILSPARI (IgAN) achieved an all-time high of 908 new patient start forms (PSFs) in Q4 2025, driven by continued demand.
• FILSPARI (IgAN) net product sales grew 108% year-over-year in 4Q 2025 to approximately $103 million.
• The company maintained a healthy cash position, ending 2025 with approximately $323 million in cash, cash equivalents, and marketable securities.
• Received a $40 million milestone payment from CSL Vifor in October 2025 for market access achievements.
• The pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU is set to restart in 1Q 2026, advancing a potentially disease-modifying therapy.
• If approved, FILSPARI would be the first and only medication for FSGS, addressing a significant unmet medical need.
• Partner Chugai Pharmaceutical expects to submit a New Drug Application for sparsentan in Japan in 2026, opening new market opportunities.

Negatives

• The FDA recently requested additional information for the sNDA seeking full approval for FILSPARI in FSGS, which could potentially impact the approval timeline or outcome.
• The financial results presented are preliminary and unaudited, subject to revision based on year-end closing procedures and external audit.

Risks

• Risks and uncertainties related to the sNDA for FILSPARI in FSGS, including the timing and outcome, with no guarantee of FDA approval on the anticipated timeline or at all.
• General business and financial risks, and the success of commercial products.
• Risks and uncertainties associated with preclinical and clinical stage pipeline development.
• Risks and uncertainties associated with the regulatory review and approval process.
• Risks and uncertainties associated with enrollment of clinical trials for rare diseases.
• Risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory, or other reasons.
• Risks associated with the ongoing commercial launch of FILSPARI in IgAN.
• Market acceptance of commercial products, including efficacy, safety, price, reimbursement, and benefit over competing therapies.
• Challenges of manufacturing scale-up.
• Risks associated with the successful development and execution of commercial strategies for products like FILSPARI.
• Risks related to the new administration, including tariffs and the funding, staffing, and prioritization of resources at government agencies like the FDA.
• Risk of being unable to raise additional funding that may be required, potentially due to macroeconomic conditions.
• Dependence on contractors for clinical drug supply and commercial manufacturing.
• Uncertainties relating to patent protection, exclusivity periods, and intellectual property rights of third parties.
• Risks associated with regulatory interactions.
• Risks and uncertainties relating to competitive products, including current and potential future generic competition, and technological changes that may limit demand.
• Additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, and potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The company is focused on sustaining the commercial momentum of FILSPARI in IgAN and preparing for a successful commercial launch in FSGS, if approved. It is well-positioned to restart the pivotal Phase 3 HARMONY Study for pegtibatinase in 1Q 2026. Travere expects to continue generating clinical evidence for FILSPARI in IgAN and its partner Chugai Pharmaceutical plans to submit a New Drug Application for sparsentan in Japan in 2026. Complete full year 2025 financial results and a corporate update are anticipated in February.

Management Comments

• "The fourth quarter closed out an exceptional year of commercial execution with FILSPARI, as our teams were able to reach a record number of patients with IgAN, reinforcing its role as foundational therapy." Eric Dube, Ph.D., president and chief executive officer.
• "As we move into 2026, we are focused on sustaining this momentum while preparing for a successful commercial launch of FILSPARI in FSGS, which, if approved, would be the first approved medication for these patients facing potential kidney failure." Eric Dube, Ph.D.
• "In addition, we are well-positioned to restart the pivotal Phase 3 HARMONY Study of pegtibatinase in the first quarter now that we have further optimized our manufacturing process. This marks an important next step in advancing our pipeline and delivering the first potentially disease-modifying therapy for people living with classical HCU." Eric Dube, Ph.D.

Industry Context

Travere Therapeutics' strong performance in the rare kidney disease market, particularly with FILSPARI for IgAN, positions it as a leader in addressing significant unmet medical needs. The potential approval of FILSPARI for FSGS and the advancement of pegtibatinase for HCU align with the broader biopharmaceutical industry trend of focusing on orphan drugs and specialized therapies, which often command premium pricing and have less competitive landscapes. The company's strategic collaborations and pipeline progress reflect a robust approach to rare disease drug development and commercialization.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong sales growth, healthy cash position, and significant pipeline progress, potentially leading to increased share value.
• **Patients (IgAN)**: Continued access to FILSPARI as a foundational therapy, with ongoing clinical evidence generation.
• **Patients (FSGS)**: Potential for the first approved medication, offering a new treatment option for a rare kidney disorder.
• **Patients (HCU)**: Progress towards a potentially disease-modifying therapy with the restart of the pivotal Phase 3 study.
• **Employees**: Positive outlook due to commercial success and pipeline advancement, fostering job security and growth opportunities.
• **CSL Vifor (Collaborator)**: Continued collaboration and potential for additional milestone payments and royalties based on market access and sales.
• **Chugai Pharmaceutical (Partner)**: Progress towards NDA submission in Japan, expanding global market reach for sparsentan.

Next Steps

• FDA review of submitted responses regarding additional information requests for FILSPARI in FSGS.
• Potential full approval and commercial launch of FILSPARI in FSGS.
• Restart of the pivotal Phase 3 HARMONY Study for pegtibatinase in classical HCU in 1Q 2026.
• Continue generating clinical evidence to support FILSPARI's role as foundational therapy in IgAN in 2026.
• Chugai Pharmaceutical to submit a New Drug Application for sparsentan in Japan in 2026.
• Announce complete full year 2025 financial results and provide a corporate update in February.
• Presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.

Key Dates

Recommendation

The company demonstrates robust commercial execution with FILSPARI, evidenced by 108% year-over-year sales growth and record patient starts, exceeding preliminary expectations. A strong cash position provides financial stability. The imminent PDUFA date for FSGS, despite a minor FDA information request, presents a near-term catalyst for market expansion into a significant unmet need. The restart of the pivotal HCU study further de-risks and advances the pipeline. These factors collectively indicate strong operational momentum and significant growth potential, making it an attractive investment.

Keywords

Travere Therapeutics, TVTX, FILSPARI, sparsentan, IgA Nephropathy, IgAN, Focal Segmental Glomerulosclerosis, FSGS, pegtibatinase, Homocystinuria, HCU, rare disease, biopharmaceutical, kidney disease, clinical trials, FDA approval, financial results, commercial launch, drug development, orphan drugs